Exploring, Predicting, and Intervening on Long-term Viral Suppression Electronically

NCT06370780 | Recruiting

• 2 other identifiers: 23-0004775UG3AI176592-02
• Study Type: interventional
• Target: 1,000
• Locations: 1 country
• Sites: 1

Brief Summary

Despite the widespread availability of effective antiretroviral therapy (ART) in the United States, there remains significant numbers of people living with HIV (PLWH) who fail to achieve and or maintain viral suppression (VS). Disparities persist with the lowest levels of VS among Black individuals, people who use drugs, youth ages 18-24 and people residing in rural areas. Investigators will examine the syndemics underlying these outcomes including substance use, mental health, and barriers to HIV care including racial discrimination, stigma and rural isolation.

Conditions

HIV Infections

Outcome Measures

Primary Outcomes (3)

• Incidence of HIV Viral Suppression

  Suppression defined as having less than 200 copies of HIV per milliliter of blood.

  past 3 months

• Level of Adherence to HIV medication

  Adherence of at least 80% to ARV medication

  past 6 months

• Level of Adherence based on HIV appointments

  Adherence defined as not missing more than 1 HIV care appointment in 1 year

  one year

Study Arms (1)

Download the REMAIN App

OTHER

All participants download the app

Other: EPI LOVE

Interventions

EPI LOVE OTHER

Observational cohort only

Download the REMAIN App

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Have access to a personal smartphone device;
• Over 18 years of age;
• Speak English or Spanish;
• Living with HIV
• Are either 1) not currently virally suppressed, 2) not currently engaged in care, or 3) have one or more factors associated with viral non suppression including a history of missed appointments or viral non suppression;
• Active substance use or mental health disorder;
• Willing and able to provide written informed consent to take part in the study.

You may not qualify if:

• Unwilling or unable to provide reliable contact information;
• Unwilling to provide blood sample for HIV virology testing;
• Living with HIV and virally suppressed and not at risk of becoming unsuppressed in the near future.

Sponsors & Collaborators

• University of California, Los Angeles: lead
• Florida State University: collaborator
• University of California, Irvine: collaborator
• University of North Carolina, Chapel Hill: collaborator
• AIDS Healthcare Foundation: collaborator
• National Institute of Allergy and Infectious Diseases (NIAID): collaborator

Study Sites (1)

University of California, Los Angeles

Los Angeles, California, 90095, United States

RECRUITING

MeSH Terms

Conditions

HIV Infections

Condition Hierarchy (Ancestors)

Blood-Borne Infections; Communicable Diseases; Infections; Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; Lentivirus Infections; Retroviridae Infections; RNA Virus Infections; Virus Diseases; Genital Diseases; Urogenital Diseases; Immunologic Deficiency Syndromes; Immune System Diseases

Study Officials

• Pamina Gorbach, DrPh

  University of California, Los Angeles

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Pamina Gorbach, DrPh

CONTACT

(628) 226-1863; RemainApp@ph.ucla.edu

Valerie El-Alfi, MA

CONTACT

RemainApp@ph.ucla.edu

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Masking Details: N/A - all participants get the app
• Purpose: OTHER
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: April 10, 2024
• First Posted: April 17, 2024
• Study Start: February 9, 2024
• Primary Completion (Estimated): April 30, 2028
• Study Completion (Estimated): April 30, 2028
• Last Updated: October 3, 2025

Record last verified: 2025-09

Locations

US (1)